Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials-Reference-Cited by-同舟云学术

Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials

Published:2018-01-22 Issue:3 Volume:21 Page:283-289
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Alquraini Hussain,del Pilar Schneider Maria,Mirakhur Beloo,Barkan Ariel^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s11102-018-0867-5/fulltext.html

Reference19 articles.

1. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89–95

2. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. Endocr Soc J Clin Endocrinol Metab 99:3933–3951

3. Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19:235–247

4. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group.: Pasireotide versus octreotide in acromegaly: a head- to-head superiority study. J Clin Endocrinol Metab 99:791–799

5. Bevan JS, Atkin SL, Atkinson AB, Bouloux P-M, Hanna F, Harris PE, James RA, McConnell M, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter trial of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor—I, and tumor size. J Clin Endocrinol Metab 87:4554–4563

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure and Function of Somatostatin and Its Receptors in Endocrinology;Endocrine Reviews;2024-08-08

2. Guidelines on diagnostics and treatment of acromegaly (draft);Obesity and metabolism;2024-06-26

3. Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas;Pharmaceuticals;2024-04-12

4. Acromegaly;The Pituitary;2022

5. CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas;International Journal of Molecular Medicine;2020-12-02